Literature DB >> 6134112

Effects of intravenous diphosphonates on renal function.

J A Kanis, C J Preston, A J Yates, R C Percival, K I Mundy, R G Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6134112     DOI： 10.1016/s0140-6736(83)92434-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Clodronate in hypercalcemia of malignancy.

Authors:  J P Bonjour; R Rizzoli
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

Review 3.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 4.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 5.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

6.  Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease.

Authors:  Nina V Lyubimova; Nikolay E Kushlinsky; Michail R Lichinitser; Karl Schlosser
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.

Authors:  L Sun; Y Li; Z Jiang; J Zhang; H Li; B Li; Z Ye
Journal:  Tumour Biol       Date:  2015-12-16

Review 8.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

9.  Treatment of malignant hypercalcaemia with clodronate.

Authors:  R C Percival; A D Paterson; A J Yates; D J Beard; D L Douglas; F E Neal; R G Russell; J A Kanis
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.